Sacituzumab Govitecan In TNBC (NCT04230109)
A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)
🩺 Plain-English Summary (8th-Grade Level)
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
Who can join: Review the eligibility criteria below.
Location: Beth Israel Deaconess Medical Center — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- Massachusetts General Hospital - North Shore Cancer Center — Danvers, Massachusetts
- Massachusetts General Hospital at Newton-Wellesley Hospital — Newton, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 726-6500
Email: LSPRING2@PARTNERS.ORG
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Invasive Breast Cancer
- Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions — Cleveland, Ohio
- Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer — Milwaukee, Wisconsin
- Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC — Atlanta, Georgia
- Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer — New York, New York
- TRUDI: TDXD+Durva in HER2+/Low IBC — Boston, Massachusetts
Explore by condition: All Invasive Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.